Clinical Trials | February 13, 2024
Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr
These re-agent and diagnostic test kits come with 99.7% accuracy
These re-agent and diagnostic test kits come with 99.7% accuracy
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
The company recently received CEP certificate approval for Losartan Potassium by EDQM
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
At least one recognised startup in every State and UT; spread across over 80% of districts
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Subscribe To Our Newsletter & Stay Updated
